Loading clinical trials...
Loading clinical trials...
Transurethral resection of bladder tumor (TURBT) is the standard therapeutic approach for patients with non-muscle-invasive bladder cancer (NMIBC). Postoperative intravesical chemotherapy or BCG immun...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Xijing Hospital
NCT07206225 · Non-muscle Invasive Bladder Cancer
NCT06510374 · Intermediate Risk Non-Muscle Invasive Bladder Cancer
NCT06245603 · Non-muscle Invasive Bladder Cancer
NCT03945162 · Non-Muscle Invasive Bladder Cancer ("NMIBC") Unresponsive/Intolerant to BCG
NCT06781879 · Non-Muscle Invasive Bladder Cancer
Xi Jing Hopspital
Xi'an, ShannxI
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions